The U.S. mammography market size was exhibited at USD 744.75 million in 2023 and is projected to hit around USD 1,810.57 million by 2033, growing at a CAGR of 9.29% during the forecast period 2024 to 2033.
Report Coverage | Details |
Market Size in 2024 | USD 813.94 Million |
Market Size by 2033 | USD 1,810.57 Million |
Growth Rate From 2024 to 2033 | CAGR of 9.29% |
Base Year | 2023 |
Forecast Period | 2024-2033 |
Segments Covered | Product, Technology, End-use |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Regional Scope | U.S. |
Key Companies Profiled | GE Healthcare; Hologic Inc.; inVivo; Vision Sciences; Adani Systems; Hausted; Lorad Chemical Corporation; RAM; iCAD; Dilon; RadNet |
The major driving factors contributed for this growth include the increasing prevalence of breast cancer, favorable government initiatives and technological advancement in screening systems.
Breast cancer consider as the most prevalent cancer among women in the U.S. and have been affecting escalating number of women. According to the American Society of Cancer statistics, approximately 30% of new female diagnosed with breast cancer each year. Approximately 310,720 new cases of invasive breast cancer are estimated to be diagnosed in women in 2024. Rising incidences of breast cancer in the U.S. contributing to market growth.
In addition, government initiatives such as awareness programs and increased funding for research and development in the field of breast cancer are expected to expand market growth. For instance, in March 2021, a new collaborative effort was introduced called the Global Breast Cancer Initiative by WHO. The main aim of this initiative is to reduce the mortality rate of breast cancer by 2.5% per year until 2040.
The U.S. mammography market accounted for around 35% of the global mammography market in 2023. The well-structured healthcare facilities and introduction of new technology advanced devices in the market are expected to increase the adoption rate among end users over the forecast period. For instance, in Decemeber 2023, UF Health Cancer Center is set to introduce a mobile mammography unit, aiming to broaden access to care and bring essential breast cancer screening services directly to communities in need.
Based on product, digital systems held the largest market share of 61.11% in 2023. This growth can be attributed to the technological advancement and high preference for breast cancer screening techniques. Hospitals, clinics and diagnostic centers are highly depend on the digital mammography screening systems. Moreover, growing government reimbursement support to key companies to improve screening efficacy is expected to accelerate the segment growth over the forecast period.
The 3D systems segment is anticipated to witness a growth at CAGR of 12% from 2024 to 2033. This growth will be driven by high efficiency, increasing need of additional screenings and rising preference to high cost detection methods. According to the 2002 FDA mammography system statistics, about 45% of 3D mammography systems are being utilized for breast cancer screening in U.S.
Based on technology, digital technology of mammography dominated the market with share of 67.15% in 2023. Increasing popularity of digital screening systems and technological advances are contributing to growth of this segment. Full-field digital mammography is advanced version of mammography, gives more clear images of micro lesions. Such features will enhance the demand of these technology over the forecast years.
The breast tomosynthesis segment is expected to grow at fastest CAGR from 20204 to 2033. The breast tomosynthesis provide 3D image in 10 seconds. These feature is likely to increase market growth. Moreover, key companies actively focusing on the manufacturing of breast tomosynthesis, contributing to demand of market.
Based on end-use, hospital held the largest market share in 2023. Hospital provides mammography screening along with hospital stays, quality of care, and the availability of emergency services, impacting positively on the market growth. Moreover, good healthcare infrastructure and provision of government policies for mammography screening anticipated to enhance opportunities for this segment’s growth.
The diagnostic centers segment is projected to expand at significant CAGR over the forecast period. The increased awareness about breast cancer, driving demand for mammography procedures used in diagnosis, treatment planning, and prevention of breast cancer. The availability of advanced mammography services in diagnostic centers. is expected to propel the market growth.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. mammography market
Product
Technology
End-use
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Technology
1.2.3. End-use
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in Italy
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Technology
2.2.3. End-use
2.3. Competitive Insights
Chapter 3. MammographyVariables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. U.S. MammographyAnalysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. U.S. Mammography Market Product Estimates & Trend Analysis
4.1. U.S. Mammography Market Product Dashboard
4.2. U.S. Mammography Market Product Movement Analysis
4.3. U.S. MammographySize & Forecasts and Trend Analyses, 2021 to 2033
4.3.1. Film Screen Systems
4.3.1.1. Film screen systems market, 2021 - 2033
4.3.2. Digital Systems
4.3.2.1. Digital systems market, 2021 - 2033
4.3.3. Analog Systems
4.3.3.1. Analog systems market, 2021 - 2033
4.3.4. 3D Systems
4.3.4.1. 3D systems market, 2021 - 2033
Chapter 5. U.S. Mammography Market: Technology Estimates & Trend Analysis
5.1. U.S. Mammography Market Technology Dashboard
5.2. U.S. Mammography Market Technology Movement Analysis
5.3. U.S. Mammography Size & Forecasts and Trend Analyses, 2021 to 2033
5.3.1. Breast Tomosynthesis Technology
5.3.1.1. Breast tomosynthesis technology market, 2021 - 2033
5.3.2. CAD Mammography Technology
5.3.2.1. CAD mammography technology market, 2021 - 2033
5.3.3. Digital Mammography Technology
5.3.3.1. Digital mammography technology market, 2021 - 2033
Chapter 6. U.S Mammography Market: End-use Estimates & Trend Analysis
6.1. U.S. Mammography Market End-use Dashboard
6.2. U.S. Mammography Market: End-use Movement Analysis
6.2.1. Hospital
6.2.1.1. Hospital market estimates and forecast, 2021 - 2033
6.2.2. Specialty Clinics
6.2.2.1. Specialty clinics market estimates and forecast, 2021 - 2033
6.2.3. Diagnostic centers
6.2.3.1. Diagnostic centers market estimates and forecast, 2021 - 2033
6.2.4. Others
6.2.4.1. Others market estimates and forecast, 2021 - 2033
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2023
7.3.4. GE Healthcare
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Hologic Inc.
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. GE Healthcare
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Hologic Inc.
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. inVivo
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Vision Sciences
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Adani Systems
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Hausted
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Lorad Chemical Corporation
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.3.13. RAM
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Product benchmarking
7.3.13.4. Strategic initiatives
7.3.14. iCAD
7.3.14.1. Company overview
7.3.14.2. Financial performance
7.3.14.3. Product benchmarking
7.3.14.4. Strategic initiatives
7.3.15. Dilon
7.3.15.1. Company overview
7.3.15.2. Financial performance
7.3.15.3. Product benchmarking
7.3.15.4. Strategic initiatives
7.3.16. RadNet
7.3.16.1. Company overview
7.3.16.2. Financial performance
7.3.16.3. Product benchmarking
7.3.16.4. Strategic initiatives